Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

NCT01918241 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-11-10

No results posted yet for this study

Summary

This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.

Conditions

Interventions

DRUG

pegfilgrastim,30mcg/kg

Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.

DRUG

pegfilgrastim, 60mcg/kg

Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.

DRUG

pegfilgrastim, 100mcg/kg

Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.

DRUG

filgrastim, 5mcg/kg

At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER
  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER
  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER
  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER
  • Wuhan TongJi Hospital

    collaborator OTHER
  • The Affiliated Hospital of Inner Mongolia Medical University

    collaborator OTHER
  • Shandong Cancer Hospital and Institute

    collaborator OTHER
  • Changsha Central Hospital

    collaborator OTHER
  • Yangzhou No.1 People's Hospital

    collaborator OTHER
  • Subei People's Hospital of Jiangsu Province

    collaborator OTHER
  • Hangzhou Jiuyuan Gene Engineering Co. Ltd.,

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01918241 on ClinicalTrials.gov